Search QCLS
Q/C TECHNOLOGIES, INC.
Nasdaq · CIK 1321834
Last close0.75
Daily change-0.03 (-3.48%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
QCLS · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
24.4Momentum
n/aAcceleration
n/aConfidence
70.0Annual Revenue7
Quarterly Revenue23
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality6.8 / 25
Capital Efficiency1.4 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 18.447 percentage points.
Key Metrics
Revenue Growth TTM-37.6%OK
Revenue CAGR 3Y-18.94%OK
Gross Margin15.36%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | n/a | -$9.85M | -$9.07M | -$10.82M | n/a | n/a | n/a | -215.05% | 1.73M |
| 2025 FY Dec 31, 2024 | n/a | n/a | -$10.17M | -$8.98M | n/a | n/a | n/a | n/a | -184.29% | 25,129 |
| 2024 FY Dec 31, 2023 | n/a | n/a | -$17.12M | -$12.98M | n/a | n/a | n/a | n/a | -156.33% | 1.54M |
| 2023 FY Dec 31, 2022 | n/a | n/a | -$15.28M | -$12.27M | n/a | n/a | n/a | n/a | -110.02% | 1.29M |
| 2022 FY Dec 31, 2021 | n/a | n/a | -$28.81M | -$19.52M | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.25M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-20-015842, 0001493152-19-017578 |
| Revenue Growth TTM | -37.6% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-20-015842, 0001493152-19-017578 |
| Revenue CAGR 3Y | -18.94% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-20-015842 |
| Revenue CAGR 5Y | -18.65% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-20-015842 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 15.36% | Gross Profit / Revenue | OK | 0001493152-20-015842, 0001493152-19-017578 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | derived |
| Current Ratio | 6.83x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001493152-21-005129 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |
| Gross Margin Delta 1Y | -18.45 pp | GrossMargin_current - GrossMargin_prior_year | OK | 0001493152-20-015842, 0001493152-19-017578 |